-
Advisory Group recommendations on priorities for the IARC Monographs Lancet Oncol. (IF 51.1) Pub Date : 2024-04-12 Amy Berrington de González, Scott A Masten, Parveen Bhatti, Renée Turzanski Fortner, Susan Peters, Tiina Santonen, Marianna G Yakubovskaya, Robert Barouki, Silvia B M Barros, Dinesh Barupal, Laura E Beane Freeman, Gloria M Calaf, Joakim Dillner, Karima El Rhazi, Lin Fritschi, Shoji Fukushima, Lode Godderis, Manolis Kogevinas, Dirk W Lachenmeier, Daniele Mandrioli, Mazvita M Muchengeti, Richard T Niemeier
-
Massive US cybersecurity breach highlights perils of health-care consolidation Lancet Oncol. (IF 51.1) Pub Date : 2024-03-14 Bryant Furlow
-
Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial Lancet Oncol. (IF 51.1) Pub Date : 2024-03-08 Arnon P Kater MD, Önder Arslan MD, Fatih Demirkan MD, Yair Herishanu MD, Burhan Ferhanoglu MD, Marcos Gonzalez Diaz MD, Brian Leber MD, Marco Montillo MD, Panayiotis Panayiotidis MD, Davide Rossi PhD, Alan Skarbnik MD, Adrian Tempescul PhD, Mehmet Turgut MD, Clemens H Mellink PhD, Anne-Marie F van der Kevie-Kersemaekers PhD, Stuart Lanham PhD, Ben Sale MSc, Luis Del Rio MSc, Relja Popovic MD, Brenda
Most patients with chronic lymphocytic leukaemia progress after treatment or retreatment with targeted therapy or chemoimmunotherapy and have limited subsequent treatment options. Response levels to the single-agent venetoclax in the relapsed setting is unknown. We aimed to assess venetoclax activity in patients with or without previous B-cell receptor-associated kinase inhibitor (BCRi) treatment.
-
Alabama Supreme Court's “extrauterine children” decision alarms oncologists and fertility experts Lancet Oncol. (IF 51.1) Pub Date : 2024-03-07 Bryant Furlow
-
Non-communicable diseases in humanitarian settings Lancet Oncol. (IF 51.1) Pub Date : 2024-03-07 Talha Burki
-
Innovation in gynaecological cancer: highlighting global disparities Lancet Oncol. (IF 51.1) Pub Date : 2024-03-07 Maria Kyrgiou, Sarah Bowden, Lynette Denny, Anna Fagotti, Nadim R Abu-Rustum, Pedro T Ramirez, Denis Querleu
-
Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled analysis Lancet Oncol. (IF 51.1) Pub Date : 2024-03-05 Bernardo Haddock Lobo Goulart MD, Sirisha L Mushti PhD, Somak Chatterjee PhD, Erin Larkins MD, Pallavi S Mishra-Kalyani PhD, Richard Pazdur MD, Paul G Kluetz MD, Harpreet Singh MD
Radiographic changes might not fully capture the treatment effects of immune checkpoint inhibitors (ICIs). We aimed to assess correlations of overall response rate and progression-free survival with overall survival in trials of ICIs for metastatic non-small-cell lung cancer (NSCLC). To assess trial-level and patient-level correlations of overall response rate and progression-free survival with overall
-
Indonesia and the Philippines take steps to control cancer Lancet Oncol. (IF 51.1) Pub Date : 2024-02-29 Manjulika Das
-
CALLA trial: immunotherapy in locally advanced cervical cancer – Authors' reply Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Bradley J Monk, Jyoti Mayadev
-
Safe and effective cancer care: how long must we wait? Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 The Lancet Oncology
-
Optimal imaging before local therapy of colorectal liver metastases – Authors' reply Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Burak Görgec, Jasper P Sijberden, Rutger-Jan Swijnenburg, Åsmund A Fretland, Cornelis Verhoef, Marc G Besselink, Jaap Stoker
-
Uncovering causal clues in the development of second primary cancers – Authors' reply Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Trille Kristina Kjaer, Christoffer Johansen, Susanne Oksbjerg Dalton
-
A pan-European total cancer prevalence canvas: a benchmark for advancing strategic interventions Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Shahrokh F Shariat
-
The Radiation Planning Assistant: addressing the global gap in radiotherapy services Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Laurence E Court
-
Harnessing stereotactic precision in the fight against primary kidney cancer: time for a randomised trial? Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Daniel X Yang, Raquibul Hannan
-
Joseph Lubega, Director of Global HOPE—building paediatric cancer care in sub-Saharan Africa Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Emma Wilkinson
-
Endpoints in human papillomavirus-related oropharyngeal cancer trials Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Marshall Posner, Scott A Roof
-
Optimal imaging before local therapy of colorectal liver metastases Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Antony Haddad, Mateo Lendoire, Iwan Paolucci, HyunSeon Christine Kang, Jean-Nicolas Vauthey
-
The need for speed: recovering undersampled MRI scans for glioma imaging Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Frederik Barkhof, Geoff JM Parker
-
Optimal imaging before local therapy of colorectal liver metastases Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Vincenza Granata, Antonella Petrillo, Sergio Venanzio Setola, Francesco Izzo, Roberta Fusco
-
Use of radiotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Sean McPhail PhD, Matthew E Barclay PhD, Ruth Swann PhD, Shane A Johnson MA, Riaz Alvi MSc, Andriana Barisic MPH, Oliver Bucher MSc, Nicola Creighton MAppStat, Cheryl A Denny MPH, Ron A Dewar MSc, David W Donnelly PhD, Jeff J Dowden MSc, Laura Downie PhD, Norah Finn MSc, Prof Anna T Gavin FFPHM, Steven Habbous PhD, Prof Dyfed W Huws MSc, S Eshwar Kumar FRCR, Leon May MPH, Carol A McClure PhD, David
There is little evidence on variation in radiotherapy use in different countries, although it is a key treatment modality for some patients with cancer. Here we aimed to examine such variation. This population-based study used data from Norway, the four UK nations (England, Northern Ireland, Scotland, and Wales), nine Canadian provinces (Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland
-
Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Sean McPhail PhD, Matthew E Barclay PhD, Shane A Johnson MA, Ruth Swann PhD, Riaz Alvi MSc, Andriana Barisic MPH, Oliver Bucher MSc, Nicola Creighton MAppStat, Cheryl A Denny MPH, Ron A Dewar MSc, David W Donnelly PhD, Jeff J Dowden MSc, Laura Downie PhD, Norah Finn MSc, Prof Anna T Gavin FFPHM, Steven Habbous PhD, Prof Dyfed W Huws MSc, Leon May MPH, Carol A McClure PhD, Bjørn Møller PhD, Grace Musto
There are few data on international variation in chemotherapy use, despite it being a key treatment type for some patients with cancer. Here, we aimed to examine the presence and size of such variation. This population-based study used data from Norway, the four UK nations (England, Northern Ireland, Scotland, and Wales), eight Canadian provinces (Alberta, British Columbia, Manitoba, Newfoundland and
-
Data sharing in cancer research: perceived risks and the consequences of not sharing Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 James T Topham, Rita T Lawlor, Diana Lemaire, Raffaella Casolino, Andrew V Biankin
-
Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Prof Shankar Siva MBBS PhD, Mathias Bressel MSc, Mark Sidhom MBBS, Swetha Sridharan MBBS, Ben G L Vanneste MD PhD, Ryan Davey PhD, Rebecca Montgomery BBiomedSc, Jeremy Ruben MbBCh, Prof Farshad Foroudi MBBS, Braden Higgs MBBS, Charles Lin MBBS, Avi Raman MBBS MPH, Nicholas Hardcastle PhD, Prof Michael S Hofman MBBS, Richard De Abreu Lourenco PhD, Mark Shaw MBChB, Pascal Mancuso MBBS, Daniel Moon MBBS
Stereotactic ablative body radiotherapy (SABR) is a novel non-invasive alternative for patients with primary renal cell cancer who do not undergo surgical resection. The FASTRACK II clinical trial investigated the efficacy of SABR for primary renal cell cancer in a phase 2 trial. This international, non-randomised, phase 2 study was conducted in seven centres in Australia and one centre in the Netherlands
-
Paraneoplastic dermatoses in a patient with gastric adenocarcinoma: cutaneous clues to internal malignancy Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Tai-Li Chen MD, Tsung-Hsien Chang MD, Cheng-Yuan Li MD
-
Surrogate endpoints in clinical trials of p16-positive squamous cell carcinoma of the oropharynx: an individual patient data meta-analysis Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Laila A Gharzai MD, Emily Morris PhD, Krithika Suresh PhD, Phuc Felix Nguyen-Tân MD, David I Rosenthal MD, Maura L Gillison MD, Paul M Harari MD, Adam S Garden MD, Shlomo Koyfman MD, Jimmy J Caudell MD, Christopher U Jones MD, Darrion L Mitchell MD, Greg Krempl MD, John A Ridge MD, Michael F Gensheimer MD, James A Bonner MD, Edith Filion MD, Neal E Dunlap MD, William A Stokes MD, Quynh-Thu Le MD, Pedro
The increased incidence of human papillomavirus (HPV)-related cancers has motivated efforts to optimise treatment for these patients with excellent prognosis. Validation of surrogates for overall survival could expedite the investigation of new therapies. We sought to evaluate candidate intermediate clinical endpoints in trials assessing definitive treatment of p16-positive oropharyngeal cancer with
-
Antibody–drug conjugates in acute myeloid leukaemia: more research needed Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Sabine Kayser
-
Accurately addressing double-arm-zero-events studies in meta-analyses – Authors' reply Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Yu Fujiwara, Nobuyuki Horita, Abdul Rafeh Naqash
-
Accurately addressing double-arm-zero-events studies in meta-analyses Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Qi Zhou, Yaolong Chen
-
CALLA trial: immunotherapy in locally advanced cervical cancer Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Xi Yang, Yuanyuan Zhang, Shuangzheng Jia, Jusheng An, Manni Huang
-
Uncovering causal clues in the development of second primary cancers Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Huan Yi, Jianguang Ji
-
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Prof Naval G Daver MD, Pau Montesinos MD, Prof Daniel J DeAngelo MD, Prof Eunice S Wang MD, Nikolaos Papadantonakis MD, Elisabetta Todisco MD, Kendra L Sweet MD, Prof Naveen Pemmaraju MD, Andrew A Lane MD, Laura Torres-Miñana MD, James E Thompson MD, Prof Marina Y Konopleva MD, Callum M Sloss PhD, Krystal Watkins MS, Gaurav Bedse PhD, Yining Du PhD, Kara E Malcolm RN, Patrick A Zweidler-McKay MD, Prof
Pivekimab sunirine (IMGN632) is a first-in-class antibody–drug conjugate comprising a high-affinity CD123 antibody, cleavable linker, and novel indolinobenzodiazepine pseudodimer payload. CD123 is overexpressed in several haematological malignancies, including acute myeloid leukaemia. We present clinical data on pivekimab sunirine in relapsed or refractory acute myeloid leukaemia. This first-in-human
-
CALLA trial: immunotherapy in locally advanced cervical cancer Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Fadila Kouhen, Mohammed Sqali Houssaini
-
Deep-learning-based reconstruction of undersampled MRI to reduce scan times: a multicentre, retrospective, cohort study Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Aditya Rastogi PhD, Gianluca Brugnara MD, Martha Foltyn-Dumitru MD, Mustafa Ahmed Mahmutoglu MD, Chandrakanth J Preetha MSc, Erich Kobler PhD, Irada Pflüger MD, Marianne Schell MD, Katerina Deike-Hofmann MD, Tobias Kessler MD, Prof Martin J van den Bent MD, Ahmed Idbaih MD, Prof Michael Platten MD, Prof Alba A Brandes MD, Prof Burt Nabors MD, Prof Roger Stupp MD, Denise Bernhardt MD, Prof Jürgen Debus
The extended acquisition times required for MRI limit its availability in resource-constrained settings. Consequently, accelerating MRI by undersampling k-space data, which is necessary to reconstruct an image, has been a long-standing but important challenge. We aimed to develop a deep convolutional neural network (dCNN) optimisation method for MRI reconstruction and to reduce scan times and evaluate
-
Radiotherapy trial quality assurance processes: a systematic review Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Chloe Brooks FRCR, Elizabeth Miles MPhil, Prof Peter J Hoskin MD
Quality assurance remains a neglected component of many trials, particularly for technical interventions, such as surgery and radiotherapy, for which quality of treatment is an important component in defining outcomes. We aimed to evaluate evidence for the processes used in radiotherapy quality assurance of clinical trials. A systematic review was undertaken focusing on use of a pre-trial outlining
-
Non-surgical ablation for breast cancer: an emerging therapeutic option Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Masakazu Toi MD PhD, Takayuki Kinoshita MD, John R Benson MD, Prof Ismail Jatoi MD, Masako Kataoka MD, Prof Wonshik Han MD, Chikako Yamauchi MD, Takashi Inamoto MD, Masahiro Takada MD
Non-surgical ablation is emerging as an alternative local therapy option for patients with early-stage breast cancer and encompasses two main types of percutaneous therapeutic procedures: radiofrequency ablation and cryoablation. Both techniques involve obliteration of a spherical lesion and feasibility studies have shown that complete tumour ablation is achievable with good or excellent cosmetic results
-
Lessons learned from postmarketing withdrawals of expedited approvals for oncology drug indications Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Simone N Koole PhD, Atse H Huisman PharmD, Lonneke Timmers PhD, Hans M Westgeest PhD, Edwin van Breugel MD, Prof Gabe S Sonke PhD, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani PhD
In the past decade, there have been a record number of oncology therapy approvals by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Besides the EMA's conditional marketing authorisation programme and the FDA's Accelerated Approval Program, we observe a tendency towards fast approval for exploratory studies with non-randomised, uncontrolled designs and surrogate endpoints
-
68Ga-RM2 PET–MRI versus MRI alone for evaluation of patients with biochemical recurrence of prostate cancer: a single-centre, single-arm, phase 2/3 imaging trial Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Heying Duan MD, Farshad Moradi MD, Guido A Davidzon MD, Tie Liang EdD, Hong Song MD, Andreas M Loening MD, Prof Shreyas Vasanawala MD, Prof Sandy Srinivas MD, Prof James D Brooks MD, Prof Steven Hancock MD, Prof Andrei Iagaru MD
National Comprehensive Cancer Network guidelines include prostate-specific membrane antigen (PSMA)-targeted PET for detection of biochemical recurrence of prostate cancer. However, targeting a single tumour characteristic might not be sufficient to reflect the full extent of disease. Gastrin releasing peptide receptors (GRPR) have been shown to be overexpressed in prostate cancer. In this study, we
-
Towards world-class radiotherapy in the UK: time for transformation Lancet Oncol. (IF 51.1) Pub Date : 2024-02-23 Katie Wakeham, Tim Cooper, Carl Rowbottom, Anthony J Chalmers, Katie Spencer, Pat Price, Sarah Quinlan
-
South Africa combats gaps in cancer data Lancet Oncol. (IF 51.1) Pub Date : 2024-02-22 Manjulika Das
-
Children and Young People Cancer Taskforce Lancet Oncol. (IF 51.1) Pub Date : 2024-02-15 Talha Burki
-
The multitarget faecal immunochemical test for improving stool-based colorectal cancer screening programmes: a Dutch population-based, paired-design, intervention study Lancet Oncol. (IF 51.1) Pub Date : 2024-02-09 Pieter H A Wisse MD, Willemijn de Klaver MD, Francine van Wifferen MSc, Frejanne G van Maaren-Meijer MSc, Huub E van Ingen MSc, Lana Meiqari MD, Iris Huitink MSc, Mariska Bierkens PhD, Margriet Lemmens BSc, Marjolein J E Greuter PhD, Prof Monique E van Leerdam MD, Prof Manon C W Spaander MD, Prof Evelien Dekker MD, Prof Veerle M H Coupé PhD, Beatriz Carvalho PhD, Meike de Wit PhD, Prof Gerrit A Meijer
The faecal immunochemical test (FIT) is widely employed for colorectal cancer screening. However, its sensitivity for advanced precursor lesions remains suboptimal. The multitarget FIT (mtFIT), measuring haemoglobin, calprotectin, and serpin family F member 2, has demonstrated enhanced sensitivity for advanced neoplasia, especially advanced adenomas, at equal specificity to FIT. This study aimed to
-
BRCA testing launched for people of Jewish ancestry in England Lancet Oncol. (IF 51.1) Pub Date : 2024-02-08 Priya Venkatesan
-
Horizon 2020 evaluation highlights benefit of cross-border research but points to areas for improvement Lancet Oncol. (IF 51.1) Pub Date : 2024-02-08 Emma Wilkinson
-
Androgen receptor agonism in advanced oestrogen receptor-positive breast cancer Lancet Oncol. (IF 51.1) Pub Date : 2024-02-08 Nan Chen, Rita Nanda
-
Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial Lancet Oncol. (IF 51.1) Pub Date : 2024-02-08 Prof Carlo Palmieri MBBS PhD, Prof Hannah Linden MD, Stephen N Birrell MBBS PhD, Sally Wheelwright PhD, Prof Elgene Lim MBBS PhD, Prof Lee S Schwartzberg MD, Amy R Dwyer PhD, Theresa E Hickey PhD, Prof Hope S Rugo MD, Patrick Cobb MD, Joyce A O'Shaughnessy MD, Prof Stephen Johnston MA PhD, Prof Adam Brufsky MD PhD, Prof Wayne D Tilley PhD, Beth Overmoyer MD
The androgen receptor is a tumour suppressor in oestrogen receptor-positive breast cancer. The activity and safety of enobosarm, an oral selective androgen receptor modulator, was evaluated in women with oestrogen receptor (ER)-positive, HER2-negative, and androgen receptor (AR)-positive disease. Women who were postmenopausal (aged ≥18 years) with previously treated ER-positive, HER2-negative, locally
-
IAEA site visit to the Zaporizhzhya Nuclear Power Plant in Ukraine Lancet Oncol. (IF 51.1) Pub Date : 2024-02-01 Manjulika Das
Abstract not available
-
HPV vaccination programme success in Scotland Lancet Oncol. (IF 51.1) Pub Date : 2024-02-01 Talha Burki
Abstract not available
-
Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial Lancet Oncol. (IF 51.1) Pub Date : 2024-01-31 Prof Kris Michael Mahadeo MD MPH, Prof Robert Baiocchi MD PhD, Amer Beitinjaneh MD, Sridhar Chaganti MD, Prof Sylvain Choquet MD, Prof Daan Dierickx MD PhD, Rajani Dinavahi MD, Xinyuan Duan MS PhD, Laurence Gamelin MD PhD, Armin Ghobadi MD, Norma Guzman-Becerra MS, Manher Joshi MD, Aditi Mehta DO, Willis H Navarro MD, Sarah Nikiforow MD PhD, Prof Richard J O'Reilly MD, Ran Reshef MD, Fiona Ruiz PhD
Survival in Epstein–Barr virus (EBV)-positive post-transplant lymphoproliferative disease following haematopoietic stem-cell transplant (HSCT) or solid organ transplant (SOT) is poor after failure of initial therapy, indicating an urgent need for therapies for this ultra-rare disease. With recent EU marketing authorisation, tabelecleucel is the first off-the-shelf, allogeneic, EBV-specific T-cell immunotherapy
-
Correction to Lancet Oncol 2020; 21: 796–807 Lancet Oncol. (IF 51.1) Pub Date : 2024-01-29
Abstract not available
-
Correction to Lancet Oncol 2023; 24: 1018–28 Lancet Oncol. (IF 51.1) Pub Date : 2024-01-29
Abstract not available
-
Strategies to promote sustainable care for children with cancer in Ukraine Lancet Oncol. (IF 51.1) Pub Date : 2024-01-30 Asya Agulnik, Yuliya Nogovitsyna, Roman Kizyma, Taisiya Yakimkova, Victoria Vivtcharenko, Nickhill Bhakta, Paul H Wise, Carlos Rodriguez-Galindo, Arman Kacharian
Abstract not available
-
Design and implementation of a humanitarian cancer care programme for Ukrainian refugees in Moldova and Romania Lancet Oncol. (IF 51.1) Pub Date : 2024-01-30 Horia Vulpe, Artiom Minzatean, Irena Tocino, Ruslan Baltaga, Gabriel Kacso, Claudia Oprea, Veronica Ciobanu, Sergiu Brenister, Ciprian Tomuleasa, Gabriel Ricu, Rodica Mindruta-Stratan, Catalin Danaila, Dragos Iancu, Ludmila Circiumari, Cristian Teglas, Lars Lonnback, Violina Nazaria, Ursula Wagner, Eugenia Ciubotaru, Nicoleta Minzatean, Ciprian Jitaru, Stanislav Polozov, Inessa Matiushenko, Anna Uzlova
Abstract not available
-
Complete cancer prevalence in Europe in 2020 by disease duration and country (EUROCARE-6): a population-based study Lancet Oncol. (IF 51.1) Pub Date : 2024-01-30 Roberta De Angelis MSc, Elena Demuru PhD, Paolo Baili MSc, Xavier Troussard MD, Alexander Katalinic MD, Maria Dolores Chirlaque Lopez PhD, Kaire Innos PhD, Mariano Santaquilani, Marcel Blum MA, Leonardo Ventura MSc, Keiu Paapsi MSc, Rocco Galasso MD, Marcela Guevara PhD, Giorgia Randi PhD, Manola Bettio PhD, Laura Botta MSc, Stefano Guzzinati MSc, Luigino Dal Maso PhD, Silvia Rossi MSc, EUROCARE-6
Cancer survivors—people living with and beyond cancer—are a growing population with different health needs depending on prognosis and time since diagnosis. Despite being increasingly necessary, complete information on cancer prevalence is not systematically available in all European countries. We aimed to fill this gap by analysing population-based cancer registry data from the EUROCARE-6 study. In
-
Treatment of metastatic pancreatic cancer: 25 years of innovation with little progress for patients Lancet Oncol. (IF 51.1) Pub Date : 2024-01-29 Bishal Gyawali, Christopher M Booth
Abstract not available
-
Modelling radiotherapy availability in the Asia-Pacific region Lancet Oncol. (IF 51.1) Pub Date : 2024-01-29 Yolande Lievens
Abstract not available
-
Accelerating progress on EU cancer control Lancet Oncol. (IF 51.1) Pub Date : 2024-01-29 Andreas Charalambous, Richard Price, Prabhat Jha
Abstract not available
-
Immunotherapy: balancing the risks and benefits Lancet Oncol. (IF 51.1) Pub Date : 2024-01-29 The Lancet Oncology
Abstract not available
-
Multiplex immunofluorescence for tumour immune biomarker discovery Lancet Oncol. (IF 51.1) Pub Date : 2024-01-29 Juha P Väyrynen
Abstract not available
-
Thank you to The Lancet Oncology's reviewers in 2023 Lancet Oncol. (IF 51.1) Pub Date : 2024-01-29 The Lancet Oncology Editors
Abstract not available